2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare use
2021
Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia.
Xiang J, Prsic E, Adelson K, Ozyck R, Prebet T. Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia. Journal Of Clinical Oncology 2021, 39: 224-224. DOI: 10.1200/jco.2020.39.28_suppl.224.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayPalliative care consultLines of therapyAdvance care planningCare consultHealthcare usePrimary teamMyeloid leukemiaCare planningAdvanced acute myeloid leukemiaPalliative care remainsPalliative care useSmilow Cancer HospitalECOG performance statusHigh-risk patientsHigher healthcare utilizationProspective cohort studyTertiary academic centerTimes/weekAML risk stratificationCriteria 1Fisher's t-test